RAGE gene polymorphisms in patients with multiple sclerosis

Journal of Molecular Neuroscience

Volumn 39, Issue 3, 2009, Pages 360-365

  Tiszlavicz, Zoltán ^a   Gyulai, Zsofia ^a,c   Bencsik, Krisztina ^a   Szolnoki, Zoltán ^b   Kocsis, Ágnes Katalin ^a   Somogyvári, Ferenc ^a   Vécsei, László ^a   Mándi, Yvette ^a  

^a UNIVERSITY OF SZEGED   (Hungary)

^b Pandy Kalman County Hospital   (Hungary)

^c NATIONAL CANCER INSTITUTE   (United States)

Author keywords

374 T A; 429 T C; G82S; Multiple sclerosis; RAGE; RFLP; SNP

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ALANINE; CYSTEINE; GLYCINE; SERINE; THREONINE;

ADULT; AMINO ACID SUBSTITUTION; ARTICLE; BLOOD DONOR; CONTROLLED STUDY; FEMALE; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOSITY; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM;

ADULT; ANTIGENS, NEOPLASM; CENTRAL NERVOUS SYSTEM; DNA MUTATIONAL ANALYSIS; FEMALE; GENE FREQUENCY; GENETIC MARKERS; GENETIC PREDISPOSITION TO DISEASE; GENETIC TESTING; GENETIC VARIATION; GENOTYPE; HOMOZYGOTE; HUMANS; MALE; MIDDLE AGED; MITOGEN-ACTIVATED PROTEIN KINASES; MULTIPLE SCLEROSIS; NERVE GROWTH FACTORS; POLYMORPHISM, GENETIC; PROTEIN BINDING; S100 PROTEINS;

EID: 73849149083     PISSN: 08958696     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12031-009-9291-7     Document Type: Article

References (26)

1. Bencsik K, Rajda C, Fuvesi J, Klivenyi P, Jardanhazy T, Torok M et al (2001) The prevalence of multiple sclerosis, distribution of clinical forms of the disease and functional status of patients in Csongrad County. Hungary Eur Neurol 46:206-209
2. Bierhaus A, Humpert PM, Morcos M, Wendt T, Chavakis T, Arnold B et al (2005) Understanding RAGE, the receptor for advanced glycation end products. J Mol Med 83:876-886
3. Bucciarelli LG, Wendt T, Rong L, Lalla E, Hofmann MA, Goova MT et al (2002) RAGE is a multiligand receptor of the immunoglobulin superfamily: implications for homeostasis and chronic disease. Cell Mol Life Sci 59:1117-1128
4. Falcone C, Campo I, Emanuele E, Buzzi MP, Geroldi D, Belvito C et al (2005) 374 T/A polymorphism of the RAGE gene promoter in relation to severity of coronary atherosclerosis. Clin Chim Acta 354:111-116
5. Hofmann MA, Drury S, Fu C, Qu W, Taguchi A, Lu Y et al (1999) RAGE mediates a novel proinflammatory axis: the cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901
6. Hofmann MA, Drury S, Hudson BI, Gleason MR, Qu W, Lu Y et al (2002) RAGE and arthritis: the G82S polymorphism amplifies the inflammatory response. Genes Immun 3:123-135
7. Hudson BI, Stickland MH, Futers TS, Grant PJ (2001) Effects of novel polymorphisms in the RAGE gene on transcriptional regulation and their association with diabetic retinopathy. Diabetes 50:1505-1511
8. Hudson BI, Stickland MH, Grant PJ (1998) Identification of polymorphisms in the receptor for advanced glycation end products (RAGE) gene. Prevalence in type 2 diabetes and ethnic groups. Diabetes 47:1155-1157
9. Kurtzke JF (1993) Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDDS). Neurology 33:1442-1452
10. Lue LF, Walker DG, Brachova L, Beach TG, Rogers J, Schmidt AM et al (2001) Involvement of microglial receptor for advanced glycation end products (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171:29-45
11. Ma L, Nicholson LFB (2004) Expression of the receptor for advanced glycation end products in Huntington's disease caudate nucleus. Brain Res 1018:10-17
12. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP, Lublin FD et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the Diagnosis of Multiple Sclerosis. Ann Neurol 50:121-127
13. Miller DH, Barkof F, Berry I, Kappos L, Scotti G, Thompson AJ et al (1991) Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. J Neurol Neurosurg Psychiatry 54:683-688
14. Park L, Raman KG, Lee KJ, Lu Y, Ferran LJ, Chow WS et al (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025- 1031
15. Poser CM, Paty DW, Scheimberg L, McDonald WI, Davis FA, Ebers GC et al (1983) New diagnostic criteria for multiple sclerosis: guidelines for research protocols. Ann Neurol 13:227-231
16. Qin J, Goswami R, Dawson S, Dawson G (2008) Expression of the receptor for advanced glycation end products in oligodendrocytes in response to oxidative stress. J Neurosci Res 86:2414-2422
17. Ramasamy R, Vannuci SJ, Yan SS, Herold K, Yan SF, Schmidt AM (2005) Advanced glycation end products and RAGE: a common thread in aging, diabetes, neurodegeneration, and inflammation. Glycobiology 15:16R-28R
18. Sasaki N, Takeuchi M, Chowei H et al (2002) Advanced glycation end products (AGE) and their receptor (RAGE) in the brain of patients with Creutzfeld-Jacob disease with prion plaques. Neurosci Lett 326:117-120
19. Sternberg Z, Weinstock-Guttman B, Hojnacji D, Zamboni P, Zivadinov R, Chadha K et al (2008) Soluble receptor for advanced glycation end products in multiple sclerosis: a potential marker of disease severity. Mult Scler 14:759-763
20. Thompson AJ, Montalban X, Barkhof F, Brochet B, Filippi M, Miller DH et al (2000) Diagnostic criteria for primary progressive multiple sclerosis: a position paper. Ann Neurol 47:831-835 (Pubitemid 30390209)
21. Tintore M, Rovira A, Martinez MJ, Rio J, Diaz-Villoslada P, Brieva L et al (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. Am J Neuroradiol 21:702-706
22. Wautier JL, Schmidt AM (2004) Protein glycation: a firm link to endothelial cell dysfunction. Circ Res 95:233-238.
23. Wautier MP, Chappey O, Corda S, Stern DM, Schmidt A, Waultier JL (2001) Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am J Physiol Endocrinol Metab 280:E685-E694.
24. Yan SD, Chen X, Fu J, Zhu HJ, Roher A, Slattery T et al (1996) RAGE and amyloid-beta peptide neurotoxicity in Alzheimer's disease. Nature 382:685-691.
25. Yan SD, Schmidt AM, Anderson GM, Zhang JH, Brett J, Zou YS et al (1994) Enhanced cellular oxidant stress by the interaction of advanced glycation end products with their receptors/binding proteins. J Biol Chem 269:9889-9897.
26. Yan SS, Wu ZY, Zhang HP, Furtado G, Chen X, Yan SF et al (2003) Suppression of experimental autoimmune encephalomyelitis by selective blockade of encephalitogenic T-cell infiltration of the central nervous system. Nat Med 9:287-293.